Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 8, 2012 - Issue 7: Special Focus: Transplantation: from tolerance to rejection
Submit an article Journal homepage
96
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

The status of fostamatinib in the treatment of rheumatoid arthritis

Jorge Morales-Torres Department of Rheumatology, Hospital Aranda de la Parra, Hidalgo 329-704, León 37000, GTO, Mexico. [email protected]
Pages 609-615 | Published online: 10 Jan 2014

References

  • MacGregor AJ, Silman AJ. Classification and epidemiology. In: Rheumatology (4th Edition). Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby Elsevier, Philadelphia, PA, USA, 755–761 (2008).
  • Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762–784 (2008).
  • McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365(23), 2205–2219 (2011).
  • Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting SYK as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13(7), 743–762 (2004).
  • Cha HS, Boyle DL, Inoue T et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J. Pharmacol. Exp. Ther. 317(2), 571–578 (2006).
  • Braselmann S, Taylor V, Zhao H et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 319(3), 998–1008 (2006).
  • Pine PR, Chang B, Schoettler N et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel SYK inhibitor. Clin. Immunol. 124(3), 244–257 (2007).
  • Sweeny DJ, Li W, Clough J et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab. Dispos. 38(7), 1166–1176 (2010).
  • Baluom M, Grossbard EB, Lau DT. Pharmacokinetics of fostamatinib, a novel SYK inhibitor in healthy human subjects following single and multiple oral dosing. Ann. Rheum. Dis. 70(Suppl. 3), 601 (2011).
  • Baluom M, Samara E, Grossbard EB, Lau DT. Fostamatinib, a SYK-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Clin. Pharmacol. 51(9), 1310–1318 (2011).
  • Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a SYK kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58(11), 3309–3318 (2008).
  • Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (SYK) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363(14), 1303–1312 (2010).
  • Genovese MC, Kavanaugh A, Weinblatt ME et al. An oral SYK kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63(2), 337–345 (2011).
  • Weinblatt ME, Kavanaugh A, Jones DA et al. Effects of the oral SYK inhibitor, fostamatinib (R788), on health-related quality of life in a Phase II study of active rheumatoid arthritis. Arthritis Rheum. 63(Suppl.), 420 (2011).
  • Kavanaugh A, Weinblatt ME, Genovese MC et al. Longer-term safety of fostamatinib (R788) in patients with rheumatoid arthritis. Analysis of clinical trial data from up to 2 years of exposure. Arthritis Rheum. 63(Suppl.), 2594(2011).
  • Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther. 13(Suppl. 1), S5 (2011).
  • Agarwal SK. Biologic agents for rheumatoid arthritis: An update for managed care professionals. J. Manag. Care Pharm. 17(Suppl. 9b), S14–S18 (2011).
  • Bajpai M, Chopra P, Dastidar SG, Ray A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin. Investig. Drugs 17(5), 641–659 (2008).
  • Bajpai M. Fostamatinib, a SYK inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 12(3), 174–185 (2009).
  • Morales-Torres J. R788 (fostamatinib disodium): a novel approach for the treatment of rheumatoid arthritis. Int. J. Clin. Rheumatology. 5, 9–15 (2010).
  • Cohen S. Small molecular therapies for rheumatoid arthritis: where do we stand? Expert Opin. Investig. Drugs 21(1), 23–31 (2012).
  • Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O’Shea JJ. Therapeutic targeting of Janus kinases. Immunol. Rev. 223, 132–142 (2008).
  • Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895–1905 (2009).
  • Cohen SB, Cheng TT, Chindalore V et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60(2), 335–344 (2009).
  • Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60(5), 1232–1241 (2009).
  • Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 9(7), 655–676 (2009).
  • Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for immunomodulation? J. Clin. Invest. 118(8), 2677–2681 (2008).
  • Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of SYK. Blood 113(14), 3154–3160 (2009).
  • Bahjat FR, Pine PR, Reitsma A et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58(5), 1433–1444 (2008).
  • Smith J, McDaid JP, Bhangal G et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J. Am. Soc. Nephrol. 21(2), 231–236 (2010).
  • Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115(13), 2578–2585 (2010).
  • Efremov DG, Laurenti L. The SYK kinase as a therapeutic target in leukemia and lymphoma. Expert Opin. Investig. Drugs 20(5), 623–636 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.